Oncotelic Therapeutics (OTCQB: OTLC) has launched an AI-powered manufacturing services platform designed to address a critical bottleneck in biotechnology: access to full Good Manufacturing Practice (GMP) infrastructure. The platform integrates Oncotelic's proprietary PDAOAI architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company's strategic automation partner. This initiative moves beyond AI's typical role in drug discovery, embedding it into manufacturing workflows that determine whether a therapy efficiently progresses from development to commercialization.
Already deployed at Oncotelic's GMP-certified SAPU manufacturing facility to support its own clinical pipeline, the platform adds a second dimension to the company's strategy. While Oncotelic remains a clinical-stage biotech, the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, this creates a services-based revenue opportunity while strengthening Oncotelic's internal development engine. Combined with TechForce Robotics' automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. The company benefits from the robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic licenses and codevelops select drug candidates through joint ventures, including a 45% ownership stake in GMP Bio, which advances its own pipeline complementing Oncotelic's strategic position in oncology and rare disease therapeutics.
For more information, visit the company's newsroom at https://ibn.fm/OTLC. The full article discussing the platform is available at https://ibn.fm/zB53J.
